Guleng Si-Ri, Wu Ri-Han, Guo Xiao-Bin
Department of Pharmacy, Inner Mongolia Autonomous Region People's Hospital, Hohhot 010010, Inner Mongolia Autonomous, China.
World J Clin Cases. 2021 Mar 6;9(7):1696-1704. doi: 10.12998/wjcc.v9.i7.1696.
Thrombocytopenia is a serious complication in the medical practice of numerous drugs. Vancomycin is frequently used for the prophylaxis and treatment of suspected or identified methicillin-resistant positive infections. Several cases with vancomycin-induced thrombocytopenia (VIT) have been reported. However, these have rarely been extensively reviewed. The present report describes a case of VIT in endocarditis, and reviews all VIT cases reported in the literature.
A 26-year-old male diagnosed with infective endocarditis was admitted. The patient was treated with multiple drugs, including vancomycin, which was initially intravenously given at 1000 mg every 12 h and subsequently at 500 mg every 8 h on day 3. On day 11, the platelet count decreased to 51 × 10/L, vancomycin was switched to 500 mg every 12 h, and platelet transfusion was given. On day 17, the platelet count dropped to 27 × 10/L, and platelet transfusion was administered again. On day 23, vancomycin was adjusted to 500 mg every 8 h as the trough concentration dropped to the minimum effective concentration. On day 33, the platelet count declined to approximately 40 × 10/L. After platelet transfusion, the platelet count rebounded to 90 × 10/L on day 35 but dropped again to 42 × 10/L on day 43. Based on the time-to-platelet count curve and Naranjo's Adverse Drug Reaction Probability Scale score, VIT was suspected. After vancomycin discontinuation and platelet transfusion, the platelet count gradually normalized.
The diagnosis of VIT can be achieved through the time-to-platelet count curve and Naranjo's Adverse Drug Reaction Probability Scale score. The platelet count cannot be normalized simply by platelet transfusion alone, and vancomycin discontinuation is essential.
血小板减少是众多药物在医学实践中的一种严重并发症。万古霉素常用于预防和治疗疑似或已确诊的耐甲氧西林阳性菌感染。已有数例万古霉素诱导的血小板减少(VIT)病例报道。然而,这些病例很少得到广泛综述。本报告描述了1例心内膜炎患者发生VIT的病例,并对文献中报道的所有VIT病例进行了综述。
一名26岁男性因感染性心内膜炎入院。患者接受了多种药物治疗,包括万古霉素,最初每12小时静脉注射1000毫克,第3天起改为每8小时静脉注射500毫克。第11天,血小板计数降至51×10⁹/L,万古霉素改为每12小时静脉注射500毫克,并给予血小板输注。第17天,血小板计数降至27×10⁹/L,再次给予血小板输注。第23天,由于谷浓度降至最低有效浓度,万古霉素调整为每8小时静脉注射500毫克。第33天,血小板计数降至约40×10⁹/L。血小板输注后,血小板计数在第35天反弹至90×10⁹/L,但在第43天再次降至42×10⁹/L。根据血小板计数时间曲线和Naranjo药物不良反应概率量表评分,怀疑为VIT。停用万古霉素并进行血小板输注后,血小板计数逐渐恢复正常。
通过血小板计数时间曲线和Naranjo药物不良反应概率量表评分可实现VIT的诊断。仅靠血小板输注不能使血小板计数恢复正常,停用万古霉素至关重要。